Jan ter Meulen

Jan ter Meulen

Company: Obsidian Therapeutics

Job title: Chief Scientific Officer


Engineering an IL2-Free, Potent & Persistent TIL With Regulated Membrane-Bound IL15 1:00 pm

• Sidestepping capillary leak syndrome associated toxicity and Treg effects • Removing the need for toxic and costly IL2 therapy associated with conventional TILs • Uncovering clinical potential as a novel TIL product with enhanced safety and efficacyRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.